Search

Search Constraints

You searched for: Author/Creator Oza, A

Search Results

1. 944PQUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. (23rd October 2018)

2. 224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). (24th November 2019)

4. Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial. (1st November 2019)

6. 5 Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. (13th November 2020)

7. 340 Performance characteristics of screening strategies to identify Lynch syndrome in women with non-serous and non-mucinous ovarian cancer. (13th November 2020)

8. 1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial. (13th November 2020)

9. 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations. (13th November 2020)

10. 263 Discordant mismatch repair protein expression in synchronous endometrial and ovarian cancers. (13th November 2020)